science
Beeline Medicines Raises $126.3 Million in Series A Extension
Bain Capital Life Sciences-backed startup Beeline Medicines secured additional funding. Separately, the acting director of the FDA office reviewing cell and gene therapies announced his departure. Both developments were reported June 30, 2026.
biopharmadive.comAudio version
Tap play to generate a narrated version.
Developing·Limited corroboration so far. This page will refresh as more sources emerge.
Beeline Medicines raised an additional $126.3 million in a Series A extension, bringing its total cash position higher after Bain Capital Life Sciences launched the startup last year with $300 million in funding, @statnews reported June 30, 2026. The new capital gives the company further resources for its drug development programs.
In a separate development the same day, Vijay Kumar is leaving his role as acting director of the office that reviews cell and gene therapies at the FDA, according to an email obtained by STAT.
The departure comes as the agency continues its work on cell and gene therapy applications.
Transparency
How sources framed this
Single source — no framing comparison available.
CorroborationModerate · 1 source
